FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe

Author:

O'Brien Siobhan12ORCID,Ubhi Tajinder12ORCID,Wolf Lucie2ORCID,Gandhi Krishna2ORCID,Lin Sichun2ORCID,Chaudary Naz34ORCID,Dhani Neesha C.3ORCID,Milosevic Michael356ORCID,Brown Grant W.12ORCID,Angers Stephane127ORCID

Affiliation:

1. 1Department of Biochemistry, University of Toronto, Ontario, Canada.

2. 2Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Ontario, Canada.

3. 3Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

4. 4Ontario Cancer Institute, Toronto, Ontario, Canada.

5. 5Department of Radiation Oncology, University of Toronto, Ontario, Canada.

6. 6Institute of Medical Science, University of Toronto, Ontario, Canada.

7. 7Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada.

Abstract

Abstract FBXW7 is a commonly mutated tumor suppressor gene that functions to regulate numerous oncogenes involved in cell-cycle regulation. Genome-wide CRISPR fitness screens identified a signature of DNA repair and DNA damage response genes as required for the growth of FBXW7-knockout cells. Guided by these findings, we show that FBXW7-mutant cells have high levels of replication stress, which results in a genotype-specific vulnerability to inhibition of the ATR signaling pathway, as these mutant cells become heavily reliant on a robust S–G2 checkpoint. ATR inhibition induces an accelerated S-phase, leading to mitotic catastrophe and cell death caused by the high replication stress present in FBXW7−/− cells. In addition, we provide evidence in cell and organoid studies, and mining of publicly available high-throughput drug screening efforts, that this genotype-specific vulnerability extends to multiple types of cancer, providing a rational means of identifying responsive patients for targeted therapy. Significance: We have elucidated the synthetic lethal interactions between FBXW7 mutation and DNA damage response genes, and highlighted the potential of ATR inhibitors as targeted therapies for cancers harboring FBXW7 alterations.

Funder

Gouvernement du Canada | Canadian Institutes of Health Research

CCS | Canadian Cancer Society Research Institute

Publisher

American Association for Cancer Research (AACR)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3